Jane Street Group LLC Increases Position in Innoviva, Inc. (NASDAQ:INVA)

Jane Street Group LLC lifted its stake in shares of Innoviva, Inc. (NASDAQ:INVA - Free Report) by 46.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 136,361 shares of the biotechnology company's stock after buying an additional 43,218 shares during the quarter. Jane Street Group LLC owned about 0.22% of Innoviva worth $2,633,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Victory Capital Management Inc. raised its stake in Innoviva by 3.5% during the 3rd quarter. Victory Capital Management Inc. now owns 140,454 shares of the biotechnology company's stock worth $2,712,000 after buying an additional 4,699 shares during the period. Segall Bryant & Hamill LLC acquired a new position in shares of Innoviva during the third quarter worth approximately $715,000. FMR LLC lifted its holdings in shares of Innoviva by 8.2% in the 3rd quarter. FMR LLC now owns 10,119 shares of the biotechnology company's stock worth $195,000 after purchasing an additional 771 shares in the last quarter. BOKF NA grew its position in Innoviva by 180.5% in the 2nd quarter. BOKF NA now owns 46,377 shares of the biotechnology company's stock valued at $761,000 after purchasing an additional 29,846 shares during the period. Finally, Caxton Associates LP increased its stake in Innoviva by 204.5% during the 2nd quarter. Caxton Associates LP now owns 108,277 shares of the biotechnology company's stock valued at $1,776,000 after purchasing an additional 72,716 shares in the last quarter. Institutional investors own 99.12% of the company's stock.

Innoviva Stock Down 0.5 %

INVA traded down $0.09 during trading on Friday, hitting $17.84. 2,400,707 shares of the company's stock were exchanged, compared to its average volume of 599,946. The stock has a market cap of $1.12 billion, a P/E ratio of 25.86 and a beta of 0.53. The business's 50 day moving average is $19.31 and its two-hundred day moving average is $18.53. Innoviva, Inc. has a fifty-two week low of $14.32 and a fifty-two week high of $21.28. The company has a quick ratio of 1.64, a current ratio of 1.79 and a debt-to-equity ratio of 0.38.

Innoviva (NASDAQ:INVA - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.27 by ($0.25). The business had revenue of $89.51 million during the quarter. Innoviva had a net margin of 18.31% and a return on equity of 20.84%. As a group, equities analysts expect that Innoviva, Inc. will post 0.33 earnings per share for the current fiscal year.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.